uniQure N.V. (QURE)

Health Care ยท Pharmaceutical Preparations

uniQure N.V. (QURE) is listed on Nasdaq, where its shares have traded since February 5, 2014. SentiSense covers uniQure N.V. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Matthew Kapusta is its chief executive officer. The company reports 221 employees, and its corporate website is www.uniqure.com.

About uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Latest reported results

uniQure N.V. reported revenue of $5.2 million for Q3 FY2026, up 40.4% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 247 institutions reported holding QURE, with 65.3 million shares worth $3.0 billion in aggregate. The largest reported holders were Avoro Capital Advisors, JPMorgan Chase and Rtw Investments. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.

More on QURE

  • QURE sentiment: whether news and social coverage of uniQure N.V. leans bullish or bearish, and the stories driving it.
  • QURE ownership: all 247 reporting institutions, plus insider and congressional trades.
  • QURE financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.

SentiSense also tracks daily options readings for uniQure N.V.: IV rank, put/call percentile, 25-delta skew and open-interest walls.

Frequently asked questions

What does uniQure N.V. do?

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases.

What sector is QURE in?

SentiSense classifies uniQure N.V. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.

Where does QURE stock trade?

uniQure N.V. (QURE) is listed on Nasdaq, where its shares have traded since February 5, 2014.

Who is the CEO of uniQure N.V.?

Matthew Kapusta is the chief executive officer of uniQure N.V..